Anaphylaxis is a severe and rapid systemic allergic reaction to a trigger substance, known an allergen. Minute amounts of trigger substances may cause a life-threatening anaphylactic reaction. Anaphylaxis may occur after ingestion, inhalation, skin contact or injection of a trigger substance. The most severe type of anaphylaxis is known as anaphylactic shock that is usually fatal, if untreated. Anaphylaxis requires immediate medical treatment, including an immediate injection of epinephrine and a trip to a hospital emergency room. Accurate diagnosis and successful management of allergies is important. Some of the drug candidates in the anaphylaxis pipeline include, but are not limited to, Epinephrine sublingual soluble film and inhalable epinephrine. Some of the companies having drugs for anaphylaxis in pipeline are, MannKind Corp., and Monosol Rx LLC.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.